Theravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.13 Per Share

Brokerages expect that Theravance Biopharma Inc (NASDAQ:TBPH) will announce earnings per share (EPS) of ($1.13) for the current quarter, according to Zacks. Three analysts have made estimates for Theravance Biopharma’s earnings, with the highest EPS estimate coming in at ($0.86) and the lowest estimate coming in at ($1.37). Theravance Biopharma reported earnings of ($1.64) per share in the same quarter last year, which suggests a positive year over year growth rate of 31.1%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that Theravance Biopharma will report full-year earnings of ($4.18) per share for the current financial year, with EPS estimates ranging from ($4.45) to ($3.93). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.53) per share, with EPS estimates ranging from ($5.57) to ($3.56). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.18) by $0.08. The company had revenue of $12.84 million for the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 505.90%.

Several research analysts have weighed in on TBPH shares. Piper Jaffray Companies reiterated a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, October 23rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $55.00 price target on shares of Theravance Biopharma in a research report on Monday, October 22nd. ValuEngine downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, November 1st. Leerink Swann set a $38.00 price target on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Finally, BidaskClub downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $43.40.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Group AG raised its position in Theravance Biopharma by 88.4% in the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 2,117 shares during the period. United Services Automobile Association bought a new position in Theravance Biopharma in the third quarter worth approximately $210,000. Xact Kapitalforvaltning AB bought a new position in Theravance Biopharma in the third quarter worth approximately $285,000. Man Group plc bought a new position in Theravance Biopharma in the third quarter worth approximately $292,000. Finally, Engineers Gate Manager LP bought a new position in Theravance Biopharma in the third quarter worth approximately $662,000. Institutional investors and hedge funds own 83.98% of the company’s stock.

Shares of Theravance Biopharma stock opened at $26.41 on Friday. The company has a market cap of $1.46 billion, a P/E ratio of -4.85 and a beta of 2.12. Theravance Biopharma has a twelve month low of $21.27 and a twelve month high of $35.48. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.08 and a current ratio of 3.26.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.

Recommended Story: Municipal Bonds

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply